April 22nd 2025
The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Catalent Secures Manufacturing Contract for Pfizer’s OTC Heartburn Treatment
December 7th 2015Catalent has entered into an exclusive long-term supply agreement to produce Pfizer’s OTC proton-pump inhibitor for heartburn treatment, Nexium 24HR (esomeprazole), which is also marketed as Nexium Control outside the US.
Clariant Invests in New Packaging Plant in India
December 2nd 2015The plant will manufacture Clariant’s moisture-control products to support the growing pharmaceutical packaging market in India.Clariant announced on Dec. 1, 2015 that it is investing CHF 10 million in a new packaging manufacturing plant in Cuddalore, India. The plant will manufacture Clariant’s moisture-control products to support the growing pharmaceutical packaging market in India.
Juniper Pharma Services Strengthens Capsule Capability with Xcelodose
December 1st 2015Xcelodose provides automated processing of API directly into capsules at low doses. The expansion of Xcelodose reinforces Juniper’s early stage capsule filling capability.CDMO Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, announced that it has expanded its Xcelodose powder micro-dosing system. This move reinforces the company’s early stage capsule filling capability.
Emerging Markets—An Opportunity for Pharma to Drive Sustainable Growth
November 26th 2015Cambridge Consultants engaged in a workshop-style dialogue with a cross section of senior personnel from both Indian and multinational pharma companies to debate whether emerging markets are an opportunity to drive sustainable growth. Conclusions from the workshop are presented in this article.
Pharma Supply Chains: Contingency Planning Not Yet a Priority, Survey Says
November 20th 2015UPS’ 2015 “Pain in the Chain” survey suggests that pharma companies are getting better at product protection, cold chain and regulatory compliance, but need to improve cost control and planning for unexpected events. Lack of transparency and “too many handoffs” remain major challenges.